Veracyte "announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023. Data being presented include new insights derived from Veracyte’s Decipher Genomics Resource for Intelligent Discovery database, which suggest potential opportunities to further personalize treatment for men with prostate cancer. Additionally, researchers will present new Decipher Prostate Genomic Classifier clinical utility data from the prospective, phase 3, randomized clinical trial, G-MINOR."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VCYT:
- Veracyte: Data show Afirma testing may help patients with thyroid nodules care
- Exagen elects Nova as Executive Chair of board of directors
- Veracyte downgraded to Market Perform from Outperform at Raymond James
- Veracyte initiated with Outperform, $33 target at Scotiabank
- Veracyte initiated with an Outperform at Scotiabank
